Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fat Emulsions, Intravenous | 24 | 2023 | 36 | 5.630 |
Why?
|
| Parenteral Nutrition, Total | 16 | 2013 | 27 | 3.520 |
Why?
|
| Fatty Acids, Omega-3 | 6 | 2024 | 41 | 2.800 |
Why?
|
| Parenteral Nutrition | 12 | 2023 | 20 | 2.710 |
Why?
|
| Drug Stability | 20 | 2024 | 145 | 1.860 |
Why?
|
| Phosphates | 6 | 2012 | 104 | 1.650 |
Why?
|
| Fish Oils | 5 | 2023 | 43 | 1.540 |
Why?
|
| Nanoparticles | 3 | 2024 | 551 | 1.530 |
Why?
|
| Triglycerides | 11 | 2024 | 248 | 1.520 |
Why?
|
| Particle Size | 18 | 2024 | 432 | 1.480 |
Why?
|
| Plastics | 7 | 2009 | 22 | 1.450 |
Why?
|
| Amino Acids | 5 | 2012 | 148 | 1.040 |
Why?
|
| Soybean Oil | 5 | 2023 | 32 | 0.980 |
Why?
|
| Emulsions | 5 | 2024 | 499 | 0.900 |
Why?
|
| Parenteral Nutrition Solutions | 3 | 2014 | 4 | 0.900 |
Why?
|
| Drug Packaging | 7 | 2009 | 11 | 0.880 |
Why?
|
| Glass | 4 | 2007 | 23 | 0.830 |
Why?
|
| Liver Failure | 1 | 2023 | 18 | 0.780 |
Why?
|
| Phytosterols | 1 | 2023 | 8 | 0.780 |
Why?
|
| Intestinal Diseases | 1 | 2023 | 38 | 0.750 |
Why?
|
| Lipids | 2 | 2024 | 329 | 0.740 |
Why?
|
| Liver | 5 | 2015 | 874 | 0.700 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2014 | 16 | 0.700 |
Why?
|
| Liver Diseases | 1 | 2023 | 157 | 0.700 |
Why?
|
| Calcium | 3 | 2009 | 584 | 0.640 |
Why?
|
| Food, Formulated | 2 | 2010 | 10 | 0.630 |
Why?
|
| Aluminum | 2 | 2012 | 13 | 0.590 |
Why?
|
| Olive Oil | 2 | 2017 | 7 | 0.570 |
Why?
|
| Potassium Compounds | 2 | 2008 | 4 | 0.560 |
Why?
|
| Glucose | 2 | 2012 | 478 | 0.550 |
Why?
|
| Drug Compounding | 4 | 2006 | 80 | 0.530 |
Why?
|
| Analysis of Variance | 8 | 2010 | 606 | 0.500 |
Why?
|
| Oxidative Stress | 3 | 2009 | 322 | 0.500 |
Why?
|
| Humans | 35 | 2024 | 65632 | 0.480 |
Why?
|
| Infant, Newborn | 10 | 2013 | 1437 | 0.410 |
Why?
|
| Guideline Adherence | 2 | 2014 | 310 | 0.410 |
Why?
|
| Drug Storage | 4 | 2009 | 23 | 0.410 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 872 | 0.390 |
Why?
|
| Liposomes | 2 | 2023 | 117 | 0.380 |
Why?
|
| Infusions, Parenteral | 3 | 2008 | 23 | 0.370 |
Why?
|
| Infant, Premature | 3 | 2011 | 199 | 0.370 |
Why?
|
| Calcium Chloride | 1 | 2012 | 19 | 0.370 |
Why?
|
| Electrolytes | 1 | 2012 | 26 | 0.370 |
Why?
|
| Hydrogen-Ion Concentration | 6 | 2010 | 465 | 0.350 |
Why?
|
| Pharmacopoeias as Topic | 5 | 2010 | 5 | 0.350 |
Why?
|
| Calcium Gluconate | 2 | 2009 | 6 | 0.350 |
Why?
|
| Chemical Phenomena | 4 | 2016 | 96 | 0.340 |
Why?
|
| Lung | 2 | 2006 | 969 | 0.320 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2024 | 37 | 0.310 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2006 | 52 | 0.300 |
Why?
|
| Solutions | 2 | 2008 | 63 | 0.300 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2009 | 40 | 0.290 |
Why?
|
| Calcium Phosphates | 1 | 2008 | 8 | 0.290 |
Why?
|
| Osmolar Concentration | 4 | 2009 | 91 | 0.280 |
Why?
|
| Chemical Precipitation | 4 | 2009 | 12 | 0.280 |
Why?
|
| Hypertriglyceridemia | 1 | 2007 | 9 | 0.270 |
Why?
|
| Time Factors | 7 | 2010 | 3776 | 0.260 |
Why?
|
| Nutritional Support | 2 | 2004 | 12 | 0.260 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2008 | 104 | 0.250 |
Why?
|
| Pharmaceutical Preparations | 2 | 2005 | 125 | 0.250 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2017 | 21 | 0.240 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2006 | 3 | 0.240 |
Why?
|
| Food | 1 | 2006 | 76 | 0.240 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 193 | 0.240 |
Why?
|
| Plant Oils | 2 | 2016 | 66 | 0.230 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2024 | 18 | 0.210 |
Why?
|
| Catholicism | 1 | 2004 | 4 | 0.210 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 25 | 0.210 |
Why?
|
| Propofol | 1 | 2004 | 21 | 0.210 |
Why?
|
| Fats | 1 | 2004 | 20 | 0.210 |
Why?
|
| Withholding Treatment | 1 | 2004 | 38 | 0.210 |
Why?
|
| Fluid Therapy | 1 | 2004 | 46 | 0.200 |
Why?
|
| Temperature | 3 | 2010 | 317 | 0.200 |
Why?
|
| Animals | 8 | 2024 | 21450 | 0.200 |
Why?
|
| Drug Incompatibility | 3 | 2008 | 3 | 0.200 |
Why?
|
| Fatty Acids | 3 | 2016 | 200 | 0.190 |
Why?
|
| Sterilization | 1 | 2003 | 15 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2009 | 624 | 0.180 |
Why?
|
| Random Allocation | 3 | 2009 | 200 | 0.180 |
Why?
|
| Injections | 3 | 2006 | 84 | 0.180 |
Why?
|
| Models, Animal | 3 | 2009 | 242 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 858 | 0.170 |
Why?
|
| Corn Oil | 1 | 2021 | 51 | 0.160 |
Why?
|
| Cell Membrane | 1 | 2023 | 506 | 0.160 |
Why?
|
| Rats | 3 | 2009 | 1996 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2023 | 436 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 2 | 2009 | 35 | 0.140 |
Why?
|
| Fatty Acids, Essential | 2 | 2015 | 8 | 0.140 |
Why?
|
| Deficiency Diseases | 2 | 2015 | 12 | 0.140 |
Why?
|
| Malondialdehyde | 2 | 2009 | 16 | 0.130 |
Why?
|
| United States | 5 | 2010 | 8165 | 0.130 |
Why?
|
| Chemistry, Physical | 2 | 2006 | 46 | 0.120 |
Why?
|
| Arachidonic Acid | 2 | 2015 | 38 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 169 | 0.110 |
Why?
|
| Safety | 2 | 2006 | 142 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 625 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 1376 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2013 | 181 | 0.090 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 31 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1041 | 0.080 |
Why?
|
| Risk Factors | 1 | 2021 | 5466 | 0.080 |
Why?
|
| Male | 6 | 2011 | 31281 | 0.080 |
Why?
|
| Inflammation | 1 | 2017 | 1195 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2319 | 0.080 |
Why?
|
| Reference Values | 1 | 2010 | 328 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2011 | 183 | 0.080 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 51 | 0.070 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 38 | 0.070 |
Why?
|
| Europe | 1 | 2009 | 199 | 0.070 |
Why?
|
| Quality Control | 1 | 2009 | 79 | 0.070 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2008 | 16 | 0.070 |
Why?
|
| Acid-Base Equilibrium | 1 | 2008 | 7 | 0.070 |
Why?
|
| Reference Standards | 1 | 2008 | 76 | 0.070 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 67 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 197 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 169 | 0.070 |
Why?
|
| Solubility | 1 | 2008 | 193 | 0.060 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2006 | 7 | 0.060 |
Why?
|
| Micronutrients | 1 | 2006 | 20 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2007 | 755 | 0.060 |
Why?
|
| Pharmaceutical Solutions | 1 | 2005 | 3 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2005 | 86 | 0.050 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2004 | 2 | 0.050 |
Why?
|
| Sulfites | 1 | 2004 | 5 | 0.050 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2003 | 21 | 0.050 |
Why?
|
| Mice | 1 | 2017 | 11172 | 0.050 |
Why?
|
| Infant | 1 | 2008 | 1710 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2003 | 11 | 0.050 |
Why?
|
| Syringes | 1 | 2003 | 12 | 0.050 |
Why?
|
| Terminal Care | 1 | 2004 | 121 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2002 | 167 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2004 | 236 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2009 | 3328 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 429 | 0.040 |
Why?
|
| Bacteria | 1 | 2003 | 337 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 1791 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2011 | 6946 | 0.040 |
Why?
|
| Protective Agents | 1 | 2017 | 12 | 0.030 |
Why?
|
| Oils | 1 | 2017 | 72 | 0.030 |
Why?
|
| Endotoxins | 1 | 2017 | 81 | 0.030 |
Why?
|
| alpha-Linolenic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Oleic Acid | 1 | 2015 | 20 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 2015 | 19 | 0.030 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2015 | 21 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2017 | 350 | 0.030 |
Why?
|
| Water | 1 | 2017 | 317 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 435 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 604 | 0.030 |
Why?
|
| Adult | 2 | 2013 | 17507 | 0.020 |
Why?
|
| Retinopathy of Prematurity | 1 | 2011 | 12 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2011 | 61 | 0.020 |
Why?
|
| Female | 2 | 2011 | 34294 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 746 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 741 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 744 | 0.020 |
Why?
|
| Sepsis | 1 | 2011 | 302 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3162 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 2639 | 0.010 |
Why?
|
| Child | 1 | 2013 | 4632 | 0.010 |
Why?
|